Mast cell stabilisers for seasonal and perennial allergic conjunctivitis
Appendices
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor: [Conjunctivitis, Allergic] this term only
#2 conjunctivitis
#3 pollen near/3 allerg*
#4 hayfever
#5 hay near/2 fever
#6 #1 or #2 or #3 or #4 or #5
#7 MeSH descriptor: [Mast Cells] explode all trees
#8 mast near/1 cell*
#9 MeSH descriptor: [Chromones] this term only
#10 MeSH descriptor: [Cromolyn Sodium] this term only
#11 (cromolyn or chromolyn) near/2 sodium
#12 (cromolyn or chromolyn) near/2 disodium
#13 (sodium or disodium) near/2 chromoglycate
#14 MeSH descriptor: [Nedocromil] this term only
#15 nedocromil sodium
#16 lodoxamide
#17 #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16
#18 #6 and #17
Appendix 2. MEDLINE (OvidSP) search strategy
1. randomized controlled trial.pt.
2. (randomized or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1‐7
9. exp animals/
10. exp humans/
11. 9 not (9 and 10)
12. 8 not 11
13. conjunctivitis, allergic/
14. conjunctivitis.tw.
15. (pollen adj3 allerg$).tw.
16. hayfever.tw.
17. (hay adj2 fever).tw.
18. or/13‐17
19. Mast Cells/
20. (mast adj1 cell$).tw.
21. chromones/
22. cromolyn sodium/
23. ((cromolyn or chromolyn) adj2 sodium).tw.
24. ((cromolyn or chromolyn) adj2 disodium).tw.
25. ((sodium or disodium) adj2 chromoglycate).tw.
26. nedocromil/
27. nedocromil sodium.tw.
28. lodoxamide.tw.
29. or/19‐28
30. 18 and 29
31. 12 and 30
The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville et al (Glanville 2006).
Appendix 3. EMBASE (OvidSP) search strategy
1. exp randomized controlled trial/
2. exp randomization/
3. exp double blind procedure/
4. exp single blind procedure/
5. random$.tw.
6. or/1‐5
7. (animal or animal experiment).sh.
8. human.sh.
9. 7 and 8
10. 7 not 9
11. 6 not 10
12. exp clinical trial/
13. (clin$ adj3 trial$).tw.
14. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.
15. exp placebo/
16. placebo$.tw.
17. random$.tw.
18. exp experimental design/
19. exp crossover procedure/
20. exp control group/
21. exp latin square design/
22. or/12‐21
23. 22 not 10
24. 23 not 11
25. exp comparative study/
26. exp evaluation/
27. exp prospective study/
28. (control$ or prospectiv$ or volunteer$).tw.
29. or/25‐28
30. 29 not 10
31. 30 not (11 or 23)
32. 11 or 24 or 31
33. exp allergic conjunctivitis/
34. conjunctivitis.tw.
35. (pollen adj3 allerg$).tw.
36. hayfever.tw.
37. (hay adj2 fever).tw.
38. or/33‐37
39. mast cell/
40. (mast adj1 cell$).tw.
41. cromoglycate disodium/
42. ((sodium or disodium) adj2 chromoglycate).tw.
43. ((cromolyn or chromolyn) adj2 sodium).tw.
44. ((cromolyn or chromolyn) adj2 disodium).tw.
45. nedocromil/
46. nedocromil sodium/
47. nedocromil sodium.tw.
48. lodoxamide.tw.
49. or/39‐48
50. 38 and 49
51. 32 and 50
Appendix 4. LILACS search strategy
allergic conjunctivitis and cromolyn or chromolyn or chromoglycate or nedocromil or lodoxamide
Appendix 5. CINAHL (EBSCO) search strategy
S29 s12 and s28
S28 s16 and s27
S27 s17 or s18 or s19 or s20 or s21 or s22 or s23 or s24 or s25 or s26
S26 TX lodoxamide
S25 TX (nedocromil n1 sodium)
S24 (MH "Nedocromil Sodium")
S23 TX ( sodium n1 chromoglycate) or (disodium n1 chromoglycate)
S22 TX (cromolyn n1 disodium) or (chromolyn n1 disodium)
S21 TX (cromolyn n1 sodium) or (chromolyn n1 sodium)
S20 (MH "Cromolyn Sodium")
S19 (MH "Chromones")
S18 TX (mast n1 cell*)
S17 (MH "Mast Cells")
S16 s13 or s14 or s15
S15 TX (hay n1 fever) or (hayfever)
S14 TX pollen n2 allerg*
S13 TX allergic conjunctivitis
S12 S1 or s2 or s3 or s4 or s5 or s6 or s7 or s8 or s9 or s10 or s11
S11 TX allocat* random*
S10 (MM "Quantitative Studies")
S9 (MM "Placebos")
S8 TX placebo*
S7 TX random* allocat*
S6 (MM "Random Assignment")
S5 TX randomi* control* trial*
S4 TX ( (singl* n1 blind*) or (singl* n1 mask*) ) or TX ( (doubl* n1 blind*) or (doubl* n1 mask*) ) or TX ( (tripl* n1 blind*) or (tripl* n1 mask*) ) or TX ( (trebl* n1 blind*) or (trebl* n1 mask*) )
S3 TX clinic* n1 trial*
S2 PT Clinical trial
S1 (MH "Clinical Trials+")
The search filter for trials at the beginning of the CINAHL strategy was developed by the Scottish Intercollegiate Guidelines Network (Sign 2010).
Appendix 6. OpenGrey search strategy
allergic conjunctivitis AND mast cell
Appendix 7. metaRegister of Controlled Trials search strategy
allergic conjunctivitis and (cromolyn or chromolyn or chromoglycate or nedocromil or lodoxamide)
Appendix 8. ClinicalTrials.gov search strategy
Allergic Conjunctivitis AND (Cromolyn OR Chromolyn OR Chromoglycate OR Nedocromil OR Lodoxamide)
Appendix 9. ICTRP search strategy
Conjunctivitis = Condition AND Cromolyn OR Chromolyn OR Chromoglycate OR Nedocromil OR Lodoxamide = Intervention
Appendix 10. IFPMA Clinical Trials Portal
allergic conjunctivitis AND mast cell
Appendix 11. Web of Science CPCI‐S search strategy
#14 #12 not #13
#13 TS= (animal OR mouse OR mice OR rat)
#12 #1 AND #11
#11 #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10
#10 TS= lodoxamide
#9 TS= nedocromil
#8 TS= disodium chromoglycate
#7 TS= sodium chromoglycate
#6 TS= chromolyn disodium
#5 TS= chromolyn sodium
#4 TS= cromolyn disodium
#3 TS= cromolyn sodium
#2 TS= mast cell
#1 TS= allergic conjunctivitis
| Adverse effect | Unfavourable outcome that occurs during or after the use of a drug or other intervention for which the causal relation between the intervention and the event is at least a reasonable possibility (Loke 2011). |
| Available case analysis | Analysis that includes data on only those whose results are known, using as a denominator the total number of people who had data recorded for the particular outcome in question (Higgins 2011a). |
| Funnel plot | Simple scatter plot of the intervention effect estimates from individual studies against some measure of each study’s size or precision (Sterne 2011). |
| Intention‐to‐treat analysis | Analysis that fulfils the next principles: |
| Unit of analysis errors | An error made in statistical analysis when the analysis does not take account of the unit of allocation. In some studies, the unit of allocation is not a person, but is instead a group of people, or parts of a person, such as eyes or teeth. Sometimes the data from these studies are analysed as if people had been allocated individually. Using individuals as the unit of analysis when groups of people are allocated can result in overly narrow confidence intervals. In meta‐analysis, it can result in studies receiving more weight than is appropriate (Green 2005). |
| Small‐study effects | A tendency for estimates of the intervention effect to be more beneficial in smaller studies (Sterne 2011). |
